This action promotes HCC progression on the one hand, but on the other hand, it sensitizes HCC cells to EGFR inhibitors and enhances the synergistic killing effects of lenvatinib combined with EGFR inhibitors. Here, EGFR is linked to hepatocellular carcinoma.